M. Wassef, F. Blei, D. Adams, A. Alomari, E. Baselga et al., Vascular anomalies classification: recommendations from the International Society for the Study of vascular anomalies, Pediatrics, vol.136, pp.203-217, 2015.

A. M. Cahill and E. L. Nijs, Pediatric vascular malformations: pathophysiology, diagnosis, and the role of interventional radiology, Cardiovasc Intervent Radiol, vol.34, pp.691-704, 2011.

S. Schulte-merker, S. A. Petrova, and T. V. , Lymphatic vascular morphogenesis in development, physiology, and disease, J Cell Biol, vol.193, pp.607-625, 2011.

L. H. Lowe, T. C. Marchant, D. C. Rivard, and A. J. Scherbel, Vascular malformations: classification and terminology the radiologist needs to know, Semin Roentgenol, vol.47, pp.106-123, 2012.

H. Vahidnezhad, Y. An, L. Uitto, and J. , Molecular genetics of the PI3K-AKTmTOR pathway in genodermatoses: diagnostic implications and treatment opportunities, J Invest Dermatol, vol.136, pp.15-23, 2016.

K. M. Keppler-noreuil, J. C. Sapp, M. J. Lindhurst, V. E. Parker, C. Blumhorst et al., Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum, Am J Med Genet A, vol.164, pp.1713-1746, 2014.

M. T. Adams, B. Saltzman, and J. A. Perkins, Head and neck lymphatic malformation treatment: a systematic review, Otolaryngol Head Neck Surg, vol.147, pp.627-666, 2012.

C. M. Giguère, N. M. Bauman, Y. Sato, D. K. Burke, J. H. Greinwald et al., Treatment of lymphangiomas with OK-432 (Picibanil) sclerotherapy: a prospective multi-institutional trial, Arch Otolaryngol Head Neck Surg, vol.128, pp.1137-1181, 2002.

B. Kasap, Sirolimus in pediatric renal transplantation, Pediatr Transplant, vol.15, pp.673-85, 2011.

S. Kobayashi, T. Kishimoto, S. Kamata, M. Otsuka, M. Miyazaki et al., Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis, Cancer Sci, vol.98, pp.726-759, 2007.

Q. Xue, J. A. Nagy, E. J. Manseau, T. L. Phung, H. F. Dvorak et al., Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6Kinase, Arterioscler Thromb Vasc Biol, vol.29, pp.1172-1180, 2009.

A. M. Hammill, M. Wentzel, A. Gupta, S. Nelson, A. Lucky et al., Sirolimus for the treatment of complicated vascular anomalies in children, Pediatr Blood Cancer, vol.57, pp.1018-1042, 2011.

H. Yuksekkaya, O. Ozbek, M. Keser, and H. Toy, Blue rubber bleb nevus syndrome: successful treatment with sirolimus, Pediatrics, vol.129, pp.1080-1084, 2012.

M. Nadal, B. Giraudeau, E. Tavernier, A. Jonville-bera, L. G. Maruani et al., Efficacy and safety of mammalian target of rapamycin inhibitors in vascular anomalies: asystematic review, Acta Derm Venereol, vol.96, pp.448-52, 2016.

D. M. Adams, A. M. Hammill, A. A. Vinks, M. N. Patel, and G. Chaudry, Efficacy and safety of Sirolimus in the treatment of complicated vascular anomalies, Pediatrics, vol.137, issue.2, 2016.

B. Feldman, E. Wang, A. Willan, and J. P. Szalai, The randomized placebo-phase design for clinical trials, J Clin Epidemiol, vol.54, pp.550-557, 2001.

B. Falissard, D. Milman, and D. Cohen, A generalization of the «lady-tasting-tea» procedure to link qualitative and quantitative approaches in psychiatric research, Int J Stat Med Res, vol.2, pp.88-93, 2013.

A. Y. Finlay and G. Khan, Dermatology life quality index (DLQI)-a simple practical measure for routine clinical use, Clin Exp Dermatol, vol.19, pp.210-216, 1994.

X. D. Chen, G. Ma, J. L. Huang, H. Chen, Y. B. Jin et al., Serum-level changes of vascular endothelial growth factor in children with infantile hemangioma after oral propranolol therapy, Pediatr Dermatol, vol.30, pp.549-53, 2013.

M. Ozeki, T. Fukao, and N. Kondo, Propranolol for intractable diffuse lymphangiomatosis, N Engl J Med, vol.364, pp.1380-1382, 2011.

D. Medici and B. R. Olsen, Rapamycin inhibits proliferation of hemangioma endothelial cells by reducing HIF-1-dependent expression of VEGF, PLoS One, vol.7, p.42913, 2012.

K. Abe, M. Shoji, J. Chen, A. Bierhaus, I. Danave et al., Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor, Proc Natl Acad Sci U S A, vol.96, pp.8663-8671, 1999.

A. L. Armesilla, E. Lorenzo, G. Del-arco, P. Martínez-martínez, S. Alfranca et al., Vascular endothelial growth factor activates nuclear factor of activated T cells in human endothelial cells: a role for tissue factor gene expression, Mol Cell Biol, vol.19, pp.2032-2075, 1999.

M. Uebelhoer, M. Nätynki, J. Kangas, A. Mendola, H. L. Nguyen et al., Venous malformation-causative TIE2 mutations mediate an AKT-dependent decrease in PDGFB, Hum Mol Genet, vol.22, pp.3438-3486, 2013.

, Law 2002-303 on patients' rights and information, 2017.